FDA Expands Indication for Xtandi to Treat Metastatic Castration-Sensitive Prostate Cancer – Renal and Urology News
The primary end point was radiographic progression-free survival (rPFS), defined as the time from randomization to radiographic disease progression at any time or death within 24 weeks after drug discontinuation.